NTGN News and Press, Neon Therapeutics Inc. From 07/15/19

Capricor Therapeutics (NASDAQ: CAPR ) +95%  on positive CAP-1002 data . More news on: Capricor Therapeutics, Inc., Galapagos NV, Neon Therapeutics, Inc., Stocks on the move, Read more ...

Thinly traded micro cap Neon Therapeutics (NASDAQ: NTGN ) is up  13%  premarket on modestly higher volume in reaction to positive topline results from a Phase 1b clinical trial, NT-001 , evaluating NEO-PV-01, its personal neoantigen vaccine candidate, combined with Bristol-Myers...

NEO-PV-01, in combination with OPDIVO® (nivolumab), broadens the immune response to specific new cancer targets, leading to the first demonstration of improved clinical durability for a personal neoantigen-based therapy in the metastatic cancer setting Demonstrated prolonged and ...

The following slide deck was published by Neon Therapeutics, Inc. in conjunction with this Read more ...

Gainers:  ReWalk Robotics (NASDAQ: RWLK ) +126% . Genocea Biosciences (NASDAQ: GNCA ) +14% . Dean Foods (NYSE: DF ) +13% . RAVE Restaurant Group (NASDAQ: RAVE ) +11% . Medley Management (NYSE: MDLY ) +10% . Neon Therapeutics (NASDAQ: NTGN ) +10% . Allena Pharmaceuticals (NASDAQ:...

CAMBRIDGE, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief Executive Officer of Neon, will present at the Jefferies 20...

The following slide deck was published by Neon Therapeutics, Inc. in conjunction with this Read more ...

Neon Therapeutics (NASDAQ: NTGN ): Q1 GAAP EPS of -$0.76  beats by $0.02 . More news on: Neon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Advancing a class-leading position in neoantigen-based therapies with ongoing progress across its multiple clinical-stage programs, pre-clinical pipeline and bioinformatics engine Expect to report in July top-line clinical results, including 12-month follow-up, from NT-001 trial of pe...

CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief Executive Officer of Neon, will present at the Bank of Ameri...